EUVIMEDEUVIMED entdecken
Crossref

Screening and confirmation of recombinant human follistatin in equine plasma for doping control purposes

Kin-Sing Wong iD, Hiu Wing Cheung iD, Yung-Ching Choi, Ning-Sum To, Terence S M Wan iD, Emmie N M Ho

Drug Testing and Analysis · 2024-03 · 16 (3) · 259-267

DOI: 10.1002/dta.3540 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Testing and Analysis, online erschienen am 04.07.2023. Verfasst von Kin-Sing Wong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N. T., Hong Kong, China. Hauptthemen laut MEDLINE: Doping in Sports. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recombinant human follistatin (rhFST) is a potential performance‐enhancing agent owing to its stimulating effect on muscle growth. Administration of rhFST to athletes is prohibited in human sports by the World Anti‐Doping Agency (WADA) and in horseracing according to Article 6 of the International Agreement on Breeding, Racing and Wagering published by the International Federation of Horseracing Authorities (IFHA). For effective control of the potential misuse of rhFST in flat racing, methods for screening and confirmatory analysis are required. This paper describes the development and validation of a complete solution for detecting rhFST and confirming its presence in plasma samples collected from racehorses. A high‐throughput analysis of rhFST with a commercially available enzyme‐linked immunosorbent assay (ELISA) was evaluated for the screening of equine plasma samples. Any suspicious finding would then be subjected to a confirmatory analysis using immunocapture, followed by nano‐liquid chromatography/high‐resolution tandem mass spectrometry (nanoLC‐MS/HRMS). The confirmation of rhFST by nanoLC‐MS/HRMS was achieved by comparing the retention times and relative abundances of three characteristic product‐ions with those from the reference standard in accordance with the industry criteria published by the Association of Official Racing Chemists. The two methods achieved comparable limit of detection (~2.5–5 ng/mL) and limit of confirmation (2.5 ng/mL or below), as well as adequate specificity, precision and reproducibility. To our knowledge, this is the first report of the screening and confirmation methods for rhFST in equine samples.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Doping in SportsHumansHorsesAnimalsTandem Mass SpectrometryReproducibility of ResultsFollistatinChromatography, Liquid

Stichwörter der Autor:innen

enzyme-linked immunosorbent assayequine plasmafollistatinimmunocapturenano-liquid chromatography/high-resolution tandem mass spectrometry

Substanzen

Follistatin

Autor:innen und Institutionen

  • Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N. T., Hong Kong, China.

ORCID-Profile: Kin-Sing Wong, Hiu Wing Cheung, Terence S M Wan

Zitieren

APA

Wong, K. S., Cheung, H. W., Choi, Y. C., To, N. S., Wan, T. S. M., & Ho, E. N. M. (2024). Screening and confirmation of recombinant human follistatin in equine plasma for doping control purposes. Drug Testing and Analysis, 16(3), 259-267. https://doi.org/10.1002/dta.3540

Vancouver

Wong KS, Cheung HW, Choi YC, To NS, Wan TSM, Ho ENM. Screening and confirmation of recombinant human follistatin in equine plasma for doping control purposes. Drug Testing and Analysis. 2024;16(3):259-267. doi:10.1002/dta.3540

BibTeX
@article{Wong2024,
  author = {Wong, Kin-Sing and Cheung, Hiu Wing and Choi, Yung-Ching and To, Ning-Sum and Wan, Terence S M and Ho, Emmie N M},
  title = {Screening and confirmation of recombinant human follistatin in equine plasma for doping control purposes},
  journal = {Drug Testing and Analysis},
  year = {2024},
  volume = {16},
  number = {3},
  pages = {259--267},
  doi = {10.1002/dta.3540}
}
Kostenlos starten →